To Prime, or Not to Prime: That Is the Question.

Mitochondrial priming is regulated by the B-cell lymphoma 2 (BCL-2) family of proteins and determines a cell's "readiness" for apoptosis. A highly primed cell will undergo apoptosis more easily than an unprimed cell in response to apoptotic stimuli via the intrinsic apoptotic pathway. Priming can be measured via BH3 profiling, which uses BH3 peptides derived from the BH3 domain of pro-apoptotic BH3-only BCL-2 family members to provoke a response from viable mitochondria. BH3 profiling can be performed on tumor cells and can identify mechanisms a cell uses to evade apoptosis and anti-apoptotic dependency to the anti-apoptotic BCL-2 family members. Priming correlates with chemosensitivity of patients in multiple cancers. Therapeutics that enhances priming of patient tumor cells ex vivo could be used to aid therapeutic decisions for patients in the future.

[1]  Ping Wang,et al.  Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy , 2016, Oncotarget.

[2]  A. Letai,et al.  iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry , 2016, Biological chemistry.

[3]  A. Letai,et al.  The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. , 2016, Blood.

[4]  Scott A. Brown,et al.  BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation , 2016, Cell.

[5]  C. Dive,et al.  Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC , 2016, Molecular Cancer Therapeutics.

[6]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[7]  Jason V. Evans,et al.  Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. , 2015, Cancer research.

[8]  A. Strasser,et al.  Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK , 2015, Cell Death and Disease.

[9]  A. Letai,et al.  Abstract 4728: Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity , 2015 .

[10]  M. Keating,et al.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia , 2015, Clinical Cancer Research.

[11]  S. Ramaswamy,et al.  Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer , 2015, Proceedings of the National Academy of Sciences.

[12]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[13]  S. Mazumder,et al.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies , 2015, Cell Death and Disease.

[14]  K. Segawa,et al.  Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure , 2014, Science.

[15]  L. Cope,et al.  Rapamycin rescues ABT-737 efficacy in small cell lung cancer. , 2014, Cancer research.

[16]  L. Stephens,et al.  BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. , 2014, Neoplasia.

[17]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[18]  J. Settleman,et al.  Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models , 2013, Molecular Cancer Therapeutics.

[19]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[20]  W. Wilson,et al.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.

[21]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[22]  I. Pollack,et al.  ABT-737 Synergizes with Bortezomib to Induce Apoptosis, Mediated by Bid Cleavage, Bax Activation, and Mitochondrial Dysfunction in an Akt-Dependent Context in Malignant Human Glioma Cell Lines , 2012, Journal of Pharmacology and Experimental Therapeutics.

[23]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[24]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Strasser,et al.  BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice , 2012, Cell Death and Differentiation.

[26]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[27]  S. Nagata,et al.  Two-Step Engulfment of Apoptotic Cells , 2011, Molecular and Cellular Biology.

[28]  A. Roberts,et al.  Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. , 2011, Blood.

[29]  W. Zong,et al.  DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity , 2011, The Journal of Immunology.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Dive,et al.  Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. , 2011, The Journal of clinical investigation.

[33]  Osamu Takeuchi,et al.  BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program , 2010, Science.

[34]  T. Kuwana,et al.  BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak* , 2010, The Journal of Biological Chemistry.

[35]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[36]  D. Green,et al.  The BCL-2 family reunion. , 2010, Molecular cell.

[37]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[38]  G. Cohen,et al.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy , 2009, Cell Death and Differentiation.

[39]  N. Fu,et al.  Baxbeta: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism. , 2009, Molecular cell.

[40]  D. Andrews,et al.  Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax , 2008, Cell.

[41]  A. Letai,et al.  Mimicking the BH3 domain to kill cancer cells , 2008, Oncogene.

[42]  C. Scott,et al.  In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas , 2008, Proceedings of the National Academy of Sciences.

[43]  W. D. Fairlie,et al.  Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands , 2008, Cell Death and Differentiation.

[44]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[45]  S. Armstrong,et al.  BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. , 2008, Blood.

[46]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[47]  C. Tse,et al.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. , 2007, Cancer research.

[48]  A. Tocilj,et al.  The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. , 2006, Molecular cell.

[49]  J. Hsieh,et al.  Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.

[50]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[51]  P. Pinton,et al.  Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum , 2006, Cell Death and Differentiation.

[52]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[53]  M. Gouy,et al.  Phylogenomics of life-or-death switches in multicellular animals: Bcl-2, BH3-Only, and BNip families of apoptotic regulators. , 2005, Molecular biology and evolution.

[54]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[55]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[56]  P. Marrack,et al.  The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. , 2003, Immunity.

[57]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[58]  B. Corfe,et al.  Damage‐induced Bax N‐terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate , 2001, The EMBO journal.

[59]  X. Wang.  The expanding role of mitochondria in apoptosis. , 2001, Genes & development.

[60]  B. Corfe,et al.  Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak , 2001, Oncogene.

[61]  V. Fadok,et al.  If phosphatidylserine is the death knell, a new phosphatidylserine-specific receptor is the bellringer , 2001, Cell Death and Differentiation.

[62]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[63]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[64]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[65]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[66]  John Savill,et al.  Corpse clearance defines the meaning of cell death , 2000, Nature.

[67]  V. Fadok,et al.  A receptor for phosphatidylserine-specific clearance of apoptotic cells , 2000, Nature.

[68]  J. Martinou,et al.  Bid Induces the Oligomerization and Insertion of Bax into the Outer Mitochondrial Membrane , 2000, Molecular and Cellular Biology.

[69]  B. Corfe,et al.  Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis , 1999, The Journal of cell biology.

[70]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[71]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[72]  A. Hsueh,et al.  Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Y. Hsu,et al.  Nonionic Detergents Induce Dimerization among Members of the Bcl-2 Family* , 1997, The Journal of Biological Chemistry.

[74]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[75]  John Calvin Reed,et al.  Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.

[76]  J. M. Boyd,et al.  Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. , 1995, Oncogene.

[77]  A. Strasser,et al.  The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[78]  Erin M. Coffee,et al.  mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. , 2014, Cancer discovery.

[79]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[80]  A. Khar,et al.  Apoptosis: An Overview , 2002 .

[81]  A. Wyllie,et al.  Apoptosis: an overview. , 1997, British medical bulletin.